2-乙酰氨基-5-溴-6-甲基吡啶 | 5860-70-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-乙酰氨基-5-溴-6-甲基吡啶
• 中文别名: 2-氨基羰基烟酸；2-氨基甲酰基吡啶-3-羧酸
• 英文名称: 2-carbamoylpyridine-3-carboxylic acid
• 英文别名: 2-carbamoylnicotinic acid；2-Aminocarbonylnicotinic acid
• CAS: 5860-70-8
• 化学式: C₇H₆N₂O₃
• mdl: MFCD00111707
• 分子量: 166.136
• InChiKey: DIABIDLZBNRSPR-UHFFFAOYSA-N

物化性质

• 熔点：
  175 °C
• 沸点：
  440.6±30.0 °C(Predicted)
• 密度：
  1.458±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  93.3
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 储存条件：
  2-8°C

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 2-CARBAMYLNICOTINIC ACID
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 5860-70-8
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
This substance is not classified as dangerous according to Directive 67/548/EEC.
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C7H6N2O3
Molecular Weight : 166,14 g/mol
CAS-No. : 5860-70-8
No components need to be disclosed according to the applicable regulations.

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Avoid
breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: -0,153
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-乙酰氨基-5-溴-6-甲基吡啶 在 sodium hypochlorite 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 14.0h， 以81.9%的产率得到2-氨基烟酸
  参考文献：
  名称：

  Design, Synthesis, and Biological Activity of a Novel Series of 2-Ureidonicotinamide Derivatives Against Influenza A Virus

  摘要：

  背景：现有抑制剂的病毒抵抗力和神经氨酸酶抑制剂的时间依赖性有效性限制了可用于预防和治疗严重流感感染的抗病毒药物数量。因此，迫切需要开发新药物来预防和治疗流感感染。 目的：本研究的目的是设计和合成一系列新型2-脲基烟酰胺衍生物，并评估它们的抗IAV活性。此外，我们预测了这些化合物抑制PA-PB1亚基的能力，并预测了这些化合物与RNA聚合酶蛋白（PDB ID 3CM8）的对接姿态。 方法：使用有机化学的经典方法合成了新设计的化合物，并在体外测试了它们抑制RNP和流感病毒的能力。此外，23种合成分子被提交给生成的药效团Hypo1，以预测RNA聚合酶的活性靶点PA-PB1亚基。ADMET药代动力学参数由Discovery Studio 2016中的ADMET模块计算。对接结果帮助我们展示了这些化合物与3CM8之间可能的相互作用。 结果：合成的2-脲基烟酰胺衍生物被表征为有效的抗流感病毒抑制剂。目标化合物7b和7c表现出显著的抗病毒活性，并可被视为抗病毒抑制剂的新型先导化合物。此外，化合物7b表现出适当的ADME性质，并基于可预测的结果和对接结果可能成为针对PA-PB1亚基的RNA聚合酶抑制剂。 结论：本研究揭示了一系列新化合物，可能有助于寻找有效的抗流感病毒药物。

  DOI：

  10.2174/0929867329666220224114627
• 作为产物：
  描述：

  pyridine-2,3-dicarboxylic anhydride 以 丁酮 为溶剂， 生成 2-乙酰氨基-5-溴-6-甲基吡啶
  参考文献：
  名称：

  Pyridazinedione compounds useful in treating neurological disorders

  摘要：

  本发明涉及吡啶并[4,5-b]喹啉及其药用盐，它们是兴奋性氨基酸拮抗剂，在需要此类拮抗作用时非常有用，例如在治疗神经系统疾病时。该发明还提供含有吡啶并[4,5-b]喹啉作为活性成分的药物组合物，以及治疗神经系统疾病的方法。

  公开号：

  US05599814A1

文献信息

• N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors
  申请人：BAGLEY SCOTT WILLIAM

  公开号：US20110111046A1

  公开（公告）日：2011-05-12

  The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R 1 , R 2 , R 3 and R 4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

  该发明提供了化合物I的化合物或其药用可接受的盐，其中R1、R2、R3和R4如本文所述；以及其药物组合物；以及在治疗受乙酰辅酶A羧化酶抑制调节的动物疾病、症状或紊乱中的使用。
• [EN] N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS<br/>[FR] INHIBITEURS DE N2-PYRAZOLOSPIROCÉTONE ACÉTYL-COA CARBOXYLASE
  申请人：PFIZER

  公开号：WO2011058473A1

  公开（公告）日：2011-05-19

  The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl- CoA carboxylase enzyme(s) in an animal.

  该发明提供了化合物(I)的结构或该化合物的药用盐，其中R1、R2、R3和R4如本文所述；以及其药物组合物；以及在治疗受乙酰辅酶A羧化酶抑制调节的动物疾病、症状或紊乱中的应用。
• Perhydrolase
  申请人：Amin Neelam S.

  公开号：US20080145353A1

  公开（公告）日：2008-06-19

  The present invention provides methods and compositions comprising at least one perhydrolase enzyme for cleaning and other applications. In some particularly preferred embodiments, the present invention provides methods and compositions for generation of peracids. The present invention finds particular use in applications involving cleaning, bleaching and disinfecting.

  本发明提供了一种包括至少一种过氧化酶酶的方法和组合物，用于清洁和其他应用。在一些特别优选实施例中，本发明提供了用于生成过氧酸的方法和组合物。本发明在涉及清洁、漂白和消毒的应用中具有特殊用途。
• Über die Eigenschaften der Nitrile der Chinolinsäure
  作者：S. Fallab、H. Erlenmeyer

  DOI：10.1002/hlca.19510340213

  日期：——

  hergestellt, für die sie die Struktur einer 3-Cyan-pyridin-carbonsäure-(2) angeben. Die Tatsache, dass sowohl diese Verbindung als auch, wie wir fanden, die von uns synthetisierte reziproke Cyan-pyridincarbonsäure bei der Decarboxylierung Nicotinsäurenitril ergeben, macht die angeführte Strukturangabe unsicher. Aus Experimenten wird abgeleitet, dass bei der Decarboxylierung der 2-Cyan-pyridin-carbon-säure-(3)

  Scheiber＆Knothe生产了一种氰基吡啶羧酸，它们表示了3-氰基吡啶羧酸的结构-（2）。该化合物以及我们发现的相互合成的氰基吡啶吡啶羧酸的对位基团在脱羧时均会生成烟腈，这一事实使得给定的结构信息不确定。由实验推导，在2-氰基-吡啶-羧酸-（3）的脱羧过程中，通过互变异构形式发生了O / NH交换。这使得那些来自Scheiber＆Kothe的人 将熔点为175-176°的酸配制成2-氰基吡啶-羧酸（3），将我们获得的熔点为184°的异构体配制成3-氰基。 -吡啶-羧酸（2）。
• Azaisatoic anhydrides
  申请人：The Sherwin-Williams Company

  公开号：US03947416A1

  公开（公告）日：1976-03-30

  A method for producing heterocyclic acid anhydrides and pyrimidinediones from the corresponding acids, dicarboxamides, 2,3-and 3,4-pyridinedicarboxamides, and N-monosubstituted 2,3-and 3,4-pyridinedicarboxamides, in which the aforesaid compounds are reacted with lead tetra-acetate in the presence of a suitable anhydrous inert solvent.

  一种从相应的酸、二羧酰胺、2,3-和3,4-吡啶二羧酰胺以及N-单取代的2,3-和3,4-吡啶二羧酰胺中制备杂环酸酐和嘧啶二酮的方法，其中上述化合物在适当无水惰性溶剂的存在下与醋酸四铅反应。

表征谱图